Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680910 · ClinicalTrials.gov registry record · Phase 1
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
A Phase 1 study of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04680910 is a Phase 1 study of Treatment-Resistant Depression that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04680910, a Phase 1 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity. We will recruit 15 participants for this open label single arm Phase I trial. All participants will undergo two propofol infusions 2-6 days apart, with each infusion maximizing expression of EEG slow waves. To minimize bias, there will be no specific gender or ethnic background consideration for enrollment. This will be a single site investigation at Washington University Medical Center.
Conditions Studied
Interventions
- DRUG Propofol
- DIAGNOSTIC_TEST Electroencephalography (EEG)
- DIAGNOSTIC_TEST Slow-Wave Activity
Study Locations (1)
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04680910
The ClinicalTrials.gov registry entry for NCT04680910 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 3 interventions - of which Propofol is the first listed.
NCT04680910 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04680910 about?
NCT04680910 is a clinical study titled "Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I". Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity. We will recruit 15 participants for this open label single arm Phase I trial. All participants will undergo two ...
What is the current status of trial NCT04680910?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-01-14. Estimated completion is 2025-07-01.
What conditions does trial NCT04680910 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT04680910?
The interventions under investigation include: Propofol (DRUG), Electroencephalography (EEG) (DIAGNOSTIC_TEST), Slow-Wave Activity (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04680910?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04680910 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DBS for Depression
RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Multiple Ascending Dose Phase 1 Study of ALA-3000
COMPLETED · Phase 1
-
Home-administered tDCS for Treatment of Depression
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.